What it's for (Indications)
- Primarily used topically for the treatment of certain superficial bacterial infections, often involving the skin or mucous membranes.
- Historically, sulphanilamide has been utilized in specific formulations, such as vaginal creams, to address bacterial vaginitis caused by susceptible organisms like *Haemophilus vaginalis*.
- It functions as a bacteriostatic agent against a range of Gram-positive and some Gram-negative bacteria by interfering with their folic acid synthesis.
- Due to the emergence of bacterial resistance and the development of more effective and safer antimicrobial agents, its systemic use has largely been superseded.
- However, its application in localized preparations persists in specific contexts where its antimicrobial spectrum and local efficacy are deemed appropriate, particularly for non-invasive or surface-level infections responsive to sulfonamides.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For topical application, such as in a vaginal cream formulation, the typical dosage involves the intravaginal administration of one applicatorful, usually once or twice daily, depending on the severity of the infection and the prescribing clinician's instructions. The duration of treatment commonly ranges from 7 to 30 days. It is crucial to complete the entire course of treatment, even if symptoms improve, to ensure eradication of the infection and prevent recurrence. Specific instructions for application, including proper hygiene and positioning, should be provided by a healthcare professional. Dosage adjustments for systemic effects are generally not necessary for appropriate topical use unless significant absorption occurs, which is rare but possible with extensive or prolonged application, particularly on compromised skin or mucous membranes. |
Safety & Warnings
Common Side Effects
- Side effects associated with topical sulphanilamide are predominantly localized and may include mild to moderate irritation at the application site, characterized by burning, itching, redness, or a rash.
- These local reactions are usually transient.
- However, due to potential systemic absorption, especially with prolonged use, application over large areas, or on abraded skin, systemic sulfonamide-related adverse effects can occur.
- These may encompass hypersensitivity reactions, ranging from skin rashes (e.
- g.
- , maculopapular, urticarial) and fever to more severe dermatological reactions.
- Other potential systemic side effects, although less common with topical administration, include photosensitivity, gastrointestinal disturbances (nausea, vomiting), and hematological changes (e.
- g.
- , leukopenia, thrombocytopenia, hemolytic anemia, particularly in G6PD deficient individuals).
- Patients should be advised to report any unusual or severe reactions promptly.
Serious Warnings
- Black Box Warning: Sulphanilamide does not carry a specific Black Box Warning issued by the U.S. Food and Drug Administration (FDA). However, it is imperative to acknowledge that as a member of the sulfonamide class of antibiotics, it shares the potential for serious, and occasionally fatal, adverse reactions that are generally associated with systemic sulfonamide therapy. These severe reactions include, but are not limited to, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias. While these severe systemic reactions are significantly less common with topical administration of sulphanilamide compared to systemic use, the risk is not entirely absent, particularly with extensive application over large body surface areas, prolonged therapy, or use on compromised or denuded skin where systemic absorption can be increased. Patients should be meticulously monitored for any signs of hypersensitivity, dermatological reactions, or hematological abnormalities, and treatment should be immediately discontinued if such symptoms manifest. This warning serves to highlight the intrinsic severe risks associated with the pharmacological class, even when used in a predominantly localized manner, and underscores the necessity of judicious prescribing and vigilant patient monitoring.
- Patients should be advised of the potential for hypersensitivity reactions to sulphanilamide or other sulfonamides, which can range from mild skin rashes to severe and life-threatening dermatological conditions.
- Discontinuation of the medication is warranted at the first sign of a rash or any other adverse reaction.
- Cross-sensitivity among sulfonamides is a known phenomenon.
- Although sulphanilamide is primarily used topically, systemic absorption can occur, particularly with extensive application, prolonged use, or on compromised skin/mucous membranes, leading to the potential for systemic effects including blood dyscrasias (e.
- g.
- , agranulocytosis, aplastic anemia), hepatic necrosis, and crystalluria.
- Patients with a history of severe allergies, asthma, or G6PD deficiency should be monitored closely.
- Photosensitivity is also a known effect, and patients should be advised to avoid direct sunlight or use protective measures.
- Caution is advised in pregnant women and nursing mothers, as systemic absorption could potentially affect the fetus or infant.
How it Works (Mechanism of Action)
Sulphanilamide exerts its therapeutic effects as a bacteriostatic antimicrobial agent by interfering with the bacterial synthesis of folic acid. It is a structural analog of para-aminobenzoic acid (PABA), which is an essential precursor for the synthesis of dihydrofolic acid, a crucial intermediate in the bacterial metabolic pathway for producing tetrahydrofolic acid. Tetrahydrofolic acid is vital for the synthesis of purines, pyrimidines, and certain amino acids, all of which are indispensable for bacterial DNA and RNA replication and protein synthesis. Sulphanilamide competitively inhibits the enzyme dihydropteroate synthase, which is responsible for incorporating PABA into the folic acid synthesis pathway. By blocking this enzymatic step, sulphanilamide effectively depletes bacterial folic acid reserves, thereby inhibiting bacterial growth and proliferation without directly killing the bacteria. This mechanism exploits the difference between bacterial and mammalian cells, as mammalian cells cannot synthesize folic acid and must obtain it exogenously.